Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$173.45 ▲ +0.00
(0.00%)
MKT CAP: $11.50B • VOL: 1.78M
52W L $23 52W H $220
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$146
MEDIAN
$194
MEAN
$198
HIGH
$236
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE TWST TAPE
TWST // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $209.87 | $199.47 | 2025-02-14 | $157.84 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $218.55 | $204.67 | 2025-02-06 | $163.04 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $197.73 | $190.80 | 2025-01-29 | $166.51 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $176.92 | — | 2025-01-17 | $169.98 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $152.64 | $164.78 | 2025-01-09 | $154.37 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $206.41 | $180.39 | 2024-12-18 | $150.90 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $168.25 | $175.18 | 2024-12-04 | $161.31 | -4.3% | 48% | C |